gene therapy
Taysha Gene Therapies Announces Positive Results for TSHA-102 in Rett Syndrome Trials
Taysha Gene Therapies, TSHA-102, Rett Syndrome, Gene Therapy, Motor Skills, Communication, Autonomic Function, Seizures
FDA’s Operation Warp Speed for Rare Diseases: First Five Participants Announced
FDA, Operation Warp Speed, Rare Diseases, START Program, Gene Therapies, Neurodegenerative Conditions
Bionova Scientific Expands into Plasmid DNA Services for Cell and Gene Therapy Developers
Bionova Scientific, Plasmid DNA, Cell and Gene Therapy, CDMO, Asahi Kasei Group, Biopharmaceuticals, Biologics, Texas Facility
Biotech Faces a Reckoning: The Challenges and Shifts in Cell Therapies
cell therapy, biotech, gene therapy, autoimmune diseases, manufacturing challenges, market acceptance, pharmaceutical industry
Ultragenyx Advances Gene Therapy for Glycogen Storage Disease Type Ia Following Phase 3 Success
Ultragenyx, gene therapy, glycogen storage disease type Ia, DTX401, Phase 3 study, GlucoGene, rare genetic diseases
BioNTech Expands ADC Alliance with MediLink, Investing $1.8 Billion
BioNTech, MediLink, ADC alliance, $1.8 billion, oligonucleotide therapy, gene therapy, molecular biology
Revolutionizing CAR-Ts: The Future of Automation and Decentralization in Cell and Gene Therapy Manufacturing
Automation, Decentralization, CAR-Ts, Cell and gene therapy manufacturing, Advanced therapies, Personalized medicine, Regulatory compliance, Quality management systems, Supply chain logistics, Digital solutions, Real-time monitoring, Patient-centered care
Evotec Discontinues Gene Therapy Operations, Shuts Down Austria Facility
Evotec, gene therapy, Austria, facility closure, strategic decision, business operations, research and development, biotechnology
How do the 12 FDA-approved gene therapies break down by medical indication
The 12 FDA-approved gene therapies cover a range of medical indications, primarily focusing on genetic disorders, cancers, and hematological conditions. Here’s a breakdown of these therapies by their medical indications: Genetic Disorders: Luxturna (voretigene neparvovec-rzyl): Approved for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, which leads to vision loss and may […]
Revolutionizing Healthcare: Streamlining Cell and Gene Therapy Manufacturing (Part 1)
Cell therapy, gene therapy, manufacturing, biotechnology, healthcare innovation, personalized medicine, production challenges, regulatory compliance, scalability, cost-effectiveness.